Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial.
Zhao H, Zhang C, Zhu Q, Chen X, Chen G, Sun W, Xiao Z, Du W, Yao J, Li G, Ji Y, Li N, Jiang Y, Wang Y, Zeng Q, Li W, Gong B, Chang X, Zhu F, Jiang X, Li J, Wu Z, Liu Y, Peng P, Wang G.
Zhao H, et al. Among authors: zhu q, zhu f.
Int Immunopharmacol. 2021 Aug;97:107702. doi: 10.1016/j.intimp.2021.107702. Epub 2021 Apr 21.
Int Immunopharmacol. 2021.
PMID: 33930706
Free PMC article.
Clinical Trial.